Health Canada has approved the first generic version of Novo Nordisk’s diabetes drug Ozempic in Canada, with Dr Reddy’s Laboratories set to market the copycat treatment. The decision comes as several drugmakers move to challenge the blockbuster GLP-1 drug with lower-cost alternatives.
The approval could test how generics compete with branded peptide drugs in Canada, where pricing is often far below brand-name medicines. Health Canada is also reviewing eight other semaglutide applications, while Sandoz has said it expects to launch its own generic version by June.
Read the original article here: https://www.msn.com/en-us/money/general/canada-approves-first-generic-version-of-ozempic-amid-rising-glp-1-competition/ar-AA21X2JM?ocid=BingNewsVerp